The Science of Megestrol Acetate Delivery

  title={The Science of Megestrol Acetate Delivery},
  author={Robert A. Femia and Richert E. Goyette},
Cachexia, usually defined as the loss of >5% of an individual’s baseline bodyweight over 2–6 months, occurs with a number of diseases that includes not only AIDS and advanced cancer but also chronic heart failure, rheumatoid arthritis, chronic obstructive pulmonary disease, Crohn disease, and renal failure. Anorexia is considered a key component of the anorexia-cachexia syndrome. Progestogens, particularly megestrol acetate, are commonly used to treat anorexia-cachexia. The mechanism of action… 
12 Citations
Using megestrol acetate to ameliorate protein-energy wasting in chronic kidney disease.
Clinical trials demonstrated the effectiveness of MA by showing increases in BMI up to 9%, albumin levels up to 1.1 g/dl, with reported protein and energy intake increases from 27% to 42%.
Cancer-associated cachexia
Cancer-associated cachexia is a disorder characterized by loss of body weight with specific losses of skeletal muscle and adipose tissue. Cachexia is driven by a variable combination of reduced food
Appetite problem in cancer patients: Pathophysiology, diagnosis, and treatment.
The pathophysiology of appetite problems in cancer patients is a complex process that involves many factors and several drugs that target those factors have been studied, however more phase 3 clinical trial studies are needed to confirm the findings from previous studies.
Megestrol acetate-loaded self-micellizing solid dispersion system for improved oral absorption and reduced food effect
Abstract The present study aimed to develop a megestrol acetate (MGA)-loaded self-micellizing solid dispersion (SMSD) employing an amphiphilic block copolymer, Soluplus®, for enhanced and consistent
Delivering anticancer drugs as carrier-free nanocrystals
Abstract Chemotherapy has remained a first-line option for treating various types of cancers. Yet, many anticancer compounds cannot freely dissolve in aqueous environments, presenting great
From Nutraceuticals to Nanoceuticals
Nanotechnology era comprises an array of food and nutritional supplements referred as nutraceuticals which are transformed to bio-enhanced “Nanoceuticals”. As India’s economy is booming and purchase


Palliative treatment of cancer anorexia with oral suspension of megestrol acetate.
Overall quality of life after the daily dose of 480-840 mg of MA was improved in 63, 56, and 55% of patients remaining on therapy after 2, 4, and 8 weeks, respectively, and appetite was the most successfully influenced parameter with an improvement in VAS in 95% of cases after 2 weeks of therapy.
Pharmacologic evaluation of megestrol acetate oral suspension in cachectic AIDS patients.
Increase in weight during the early stages of megestrol acetate therapy is related to the extent of in vivo drug exposure above a threshold concentration, according to a statistically significant correlation between the ratio of body weight at 3 weeks/initial weight (weight index) and the percentage of the 24-h dosing interval that megestro acetate concentrations exceeded a 300-ng/ml threshold.
A Review of the Drug Treatment of Cachexia Associated with Cancer
There is now the possibility of addressing this fascinating syndrome at a different level and an opportunity for combined therapy to try to improve the quality of life of these patients.
Appetite stimulation and weight gain with megestrol acetate.
It was concluded that, although megestrol acetate cannot be expected to directly affect the prognosis of patients with hormone-insensitive tumors, it may increase host resistance by improving nutritional status and/or enhancing the quality of life.
Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia.
A positive dose-response effect for megestrol acetate on appetite stimulation supports both the prestudy hypothesis and other available literature and it is reasonable to use 160 mg/d for the initial treatment of cancer anorexia/cachexia in routine clinical practice.
Osteoporosis associated with megestrol acetate.
2 patients who recently presented to the Metabolic Bone Disease Clinic with severe osteoporosis complicated by multiple vertebral fractures experienced while the patients were receiving high-dose megestrol therapy are described.
Medroxyprogesterone acetate reduces the production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients.
Medroxyprogesterone acetate (MEA) is widely used in oncology both in the treatment of hormonerelated cancers and as supportive therapy in anorexialcachexia syndrome (ACS), but conclusive data are not
Treating malnutrition with megestrol acetate: literature review and review of our experience.
The authors review the evidence available to support the use of megestrol acetate in treating malnutrition in older persons, in patients on dialysis and in a number of other situations, and the problems associated with administering megestro acetate.
Cancer anorexia-cachexia syndrome: are neuropeptides the key?
  • A. Inui
  • Biology, Medicine
    Cancer research
  • 1999
Although therapeutic intervention using neuropeptide agonists/antagonists is now directed at obesity treatment, it may also have an effect on treating cancer anorexia-cachexia, especially when combined with other agents that have effects on muscle and protein breakdown.
Orexigenic and anabolic agents.
  • J. Morley
  • Medicine
    Clinics in geriatric medicine
  • 2002
An approach to the management of anorexia and weight loss in older persons is given and mirtazapine seems to be the antidepressant of choice and the use of taste enhancers can be considered in persons who complain that the food does not taste good.